Skip to content

Efficacy and Cost-effectiveness of Brain-Machine Interface Therapy in Stroke Patients with Upper-extremity Paralysis

Efficacy and Cost-effectiveness of Brain-Machine Interface Therapy in Stroke Patients with Upper-extremity Paralysis: A Single-blind Randomized Controlled Trial - ECOBITS Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000057216
Enrollment
116
Registered
2025-03-12
Start date
2025-03-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke (Cerebral Infarction,Intracerebral Hemorrhage,Subarachnoid Hemorrhage)

Interventions

Brain-Machine Interface (BMI) therapy for 20 minutes/session, 5 sessions/week for 4 weeks (total 20 sessions) plus conventional rehabilitation Conventional rehabilitation including electrical stimulat

Sponsors

Heisei Medical Welfare Group Research Institute
Lead Sponsor
LIFESCAPES Inc.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Stroke patients (hemorrhage, infarction, or subarachnoid hemorrhage) within 60 days of onset 2. Severe upper limb paresis: Passive extension range of motion >= -10 degrees at fingers' MP joints Initial FMA-UE (upper extremity motor function score) <= 30 3. Age >= 18 years 4. Capable of providing informed consent (for patients with motor aphasia, consent can be obtained by proxy after confirming patient's understanding using SLTA)

Exclusion criteria

Exclusion criteria: 1. Patients unable to undergo rehabilitation (neurological diseases, severe comorbidities, cognitive dysfunction [MMSE<21, except for motor aphasia], psychiatric disorders) 2. Patients with cardiac pacemaker or implantable cardioverter-defibrillator 3. Patients who participated in another clinical trial or clinical research within the year prior to participating in the research 4. Prior botulinum toxin therapy or nerve block before enrollment 5. Patients unable to undergo EEG measurement

Design outcomes

Primary

MeasureTime frame
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) motor score at day 30 after randomization

Secondary

MeasureTime frame
FMA-UE subscales, sensory assessment (10-point scale), Modified Ashworth Scale, Functional Independence Measure, finger muscle EMG, EQ-5D-5L

Countries

Japan

Contacts

Public ContactNoriko Kanasaki

Heisei Medical Welfare Group Research Institute Administrative division

kanasaki.noriko@hmw.gr.jp+81-3-6712-6401

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026